Rakuten Medical company information, Employees & Contact Information

Rakuten Medical Expands Patient Recruitment to Japan and Prepares for Expansion to Eastern Europe in Global Phase 3 Trial of ASP-1929 Photoimmunotherapy Combined with Pembrolizumab for 1L Recurrent Head and Neck Cancer Rakuten Medical

Rakuten Medical Announces Publication in Head & Neck of Phase 1b/2 Clinical Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab Rakuten Medical

Rakuten Medical Strengthens Executive Team with Appointment of CFO Andrew Liu Rakuten Medical

Rakuten Medical Completes Technology Transfer of IR700 Manufacturing and Establishes Exclusive Position in its Supply - Rakuten Medical - To conquer cancer. Rakuten Medical

Rakuten Medical Announces Initiation of Global Phase 3 Trial of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for First-Line Recurrent Head and Neck Cancer Rakuten Medical

Announces Commercialization of Medical Devices “BioBlade™ Laser WR” and “BioBlade SideFire Diffuser ™” in Japan for Photoimmunotherapy for Head and Neck Cancer based upon its Alluminox Platform - Rakuten Medical - To conquer cancer. Rakuten Medical

Rakuten Medical Presented Research Results of Preclinical Studies for PD-L1-Targeted Photoimmunotherapy at The 83rd Annual Meeting of The Japanese Cancer Association 2024 Rakuten Medical

Rakuten Medical Closes $119 Million Series E Financing to Further Develop its Alluminox™ Platform Rakuten Medical

First Safety and Efficacy Data of Rakuten Medical’s Alluminox Treatment using ASP-1929 in Combination with anti-PD-1 for Recurrent and/or Metastatic Head and Neck Cancer Presented at AHNS 2023 Rakuten Medical

Rakuten Medical Announces Recent Interim Data from Phase 1b/2 Clinical Trial of ASP-1929 Photoimmunotherapy in Combination with anti-PD-1 for First Line Recurrent and/or Metastatic Head and Neck Cancer to be Presented at ASCO 2024 Rakuten Medical

Announces FDA Acceptance of an Investigational New Drug (IND) Application for RM-1995, a Conjugate of IR700 and anti-CD25 Antibody - Rakuten Medical - To conquer cancer. Rakuten Medical

Rakuten Medical Announces New Management Team to Drive the Next Phase of Growth and Innovation Rakuten Medical

Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the Middle East and North Africa Rakuten Medical

Rakuten Medical Announces New Name “Alluminox™” for its Proprietary Technology Platform Rakuten Medical

Three Invited Presentations on Alluminox Treatment (Photoimmunotherapy) at FHNO 2023 Rakuten Medical

Rakuten Medical R&D Day shared comprehensive overview of investigational Alluminox™ platform and the promising scientific and clinical data for ASP-1929/RM-1929 based on the platform Rakuten Medical

With the Establishment of India Entity, Mickey Mikitani, Co-CEO of Rakuten Medical Visits Respected Medical Institutions in India Rakuten Medical

Rakuten Medical, Inc. Closes $166 Million Series D Financing led by General Catalyst Rakuten Medical

Rakuten Medical and Karkinos Healthcare Announce Strategic Partnership to Expand the Reach of Novel Cancer Care in India Rakuten Medical

Announces First Patient Treatment in India in Global Phase 3 Trial of Alluminox Treatment (Photoimmunotherapy) using ASP-1929 for Recurrent Head and Neck Cancer - Rakuten Medical - To conquer cancer. Rakuten Medical

Rakuten Medical Taiwan Announces Commencing a Phase 2 Clinical Trial for Head and Neck Squamous Cell Carcinoma Photoimmunotherapy based on the Alluminox™ platform at 5 Leading Medical Centers and the Enrollment of First Patient Rakuten Medical

Rakuten Medical Participates in the J.P. Morgan Global Healthcare Conference, Shanghai Forum Rakuten Medical

Over 20 Presentations on Alluminox Treatment (Photoimmunotherapy) at International Conferences in 2023 Rakuten Medical

to Start a Global Phase 3 Trial of Alluminox™ Treatment using ASP-1929 for Recurrent Head and Neck Cancer in India - Rakuten Medical - To conquer cancer. Rakuten Medical

Rakuten Medical to commence a Phase 1 Trial of Alluminox™ Treatment Utilizing Anti-CD25 Antibody-Dye Conjugate, RM-1995, Targeting Regulatory T Cells in the Treatment of Advanced or Recurrent Solid Tumors with Liver Metastasis in Japan Rakuten Medical

Rakuten Medical aims to transform head and neck cancer treatments in India Rakuten Medical

Rakuten Medical and Shimadzu Enroll First Patient in the U.S. Clinical Trial of Photoimmunotherapy Rakuten Medical

Mickey Mikitani gives keynote at India Head & Neck Oncology Conference “FHNO2022”, Rakuten Medical also releases new video about the Alluminox™ platform Rakuten Medical

Data from Phase 1/2a study of RM-1929 Photoimmunotherapy in Patients with Recurrent Head and Neck Squamous Cell Carcinoma was Published in Head and Neck Rakuten Medical

Rakuten Medical Opens two new Offices in the Netherlands and Taiwan, Adding new Jobs to Strengthen and Expand its Global Presence Rakuten Medical

Rakuten Medical celebrates its 10-year anniversary - Rakuten Medical - To conquer cancer. Rakuten Medical

Ecommerce Company Rakuten Invests $100 Million in Rakuten Medical, Increasing Equity Share to 22.5% Rakuten Medical

Japan Announces Commercialization of Akalux® IV Infusion 250mg and BioBlade® Laser System in Japan - Rakuten Medical - To conquer cancer. Rakuten Medical

Rakuten Medical, Inc. Acquires Key Assets and Manufacturing Technology from LI-COR Biosciences Rakuten Medical

closes deal with Merck KGaA, Darmstadt, Germany to receive cetuximab for production of Rakuten Medical’s ASP-1929 antibody-drug conjugate - Rakuten Medical - To conquer cancer. Rakuten Medical

Rakuten Aspyrian Announces Name Change to Rakuten Medical - Rakuten Medical - To conquer cancer. Rakuten Medical

Rakuten Medical Stories Rakuten Medical

Rakuten Medical appoints David Chao and Kentaro Hyakuno to its Board of Directors, Welcomes new CFO and General Counsel to Executive Leadership Team Rakuten Medical